Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-country Real-World Observational Study of MIrvetuximab Soravtansine in Treating Platinum-REsistant FRALphA Positive Ovarian, Fallopian Tube, and Peritoneal Cancer- MIRELA

NCT07896421 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07896421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-country Real-World Observational Study of MIrvetuximab Soravtansine in Treating Platinum-REsistant FRALphA Positive Ovarian, Fallopian Tube, and Peritoneal Cancer- MIRELA
Lead sponsor
AbbVie
Phase
Observational
Overall status
Recruiting
Start date
October 21, 2026
Completion date
April 30, 2030
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant frα-positive fallopian tube cancer, platinum-resistant frα-positive ovarian cancer, platinum-resistant frα-positive peritoneal cancer

Arms

As registered; 1 arm.

  • Mirvetuximab Soravtansine (MIRV)

    Participants with FRα positive platinum-resistant ovarian, primary peritoneal or fallopian tube cancer and are scheduled to receive treatment with MIRV in accordance with the local label of the participating country.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Treatment Duration of MIRV Among Participants With Platinum-Resistant FRα-Positive Ovarian Cancer Up to approximately 18 months

    Treatment duration of MIRV is defined as (the maximum end date of MIRV dosing date - the minimum start date of MIRV +21).

Lead sponsor's other trials

AbbVie, most recent start first.

Similar trials

Same condition (Fallopian Tube Neoplasms) and phase, most recent start first.